Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 77pembrolizumab 59Carboplatin 57Bevacizumab 57Specimen Handling 48Magnetic Resonance Spectroscopy 39Cisplatin 32olaparib 31Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 19Topotecan 17Nivolumab 17Cyclophosphamide 16Immunoglobulin G 15Doxorubicin 15Disulfides 15niraparib 12fludarabine 12Surveys and Questionnaires 12Letrozole 12lenvatinib 11durvalumab 11atezolizumab 11Fulvestrant 10Drug Therapy 10abemaciclib 9Docetaxel 9Brachytherapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pamiparib × Gynecologic × 90 days × Clear all
NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

BeOne Medicines

Phase 3 Active not recruiting
224 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡